How I Use SGLT2 Inhibitors in T2D for Cardiovascular and Renal Disease
  • CME
  • CE

SGLT2 inhibitors play important roles in our new person-centric approach for managing T2D. Here’s my take on how SGLT2 inhibitors can be used to mitigate cardiovascular and renal disease, along with how I approach treatment selection in challenging clinical scenarios.
Martin J. Abrahamson, MD, FACP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: November 10, 2020 Expiration: November 9, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of SGLT2-I drugs in patients with varying degrees of CV and/or renal risk
  • Consider the key clinical evidence from CVOTs with SGLT2-I drugs in management decisions for patients with T2D

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from Novo Nordisk.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is primarily intended for endocrinologists, primary care physicians, and nurses who care for patients with T2D.

Goal

The goal of this activity is to improve learners’ competence and performance in SGLT2-I treatment decisions for patients with T2D with and without related comorbidities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 10, 2020, through November 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CME commentary: GLP-1 receptor agonists and weight reduction in diabetes. Evidence for exenatide, dulaglutide, liraglutide, semaglutide in T2D and obesity.

Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: October 26, 2020 Expired: October 25, 2021

Expert recommendations from Clinical Care Options on using oral semaglutide to treat type 2 diabetes

Richard E. Pratley, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: October 22, 2020 Expired: October 21, 2021

Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021

Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Neil Skolnik, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Nurse Practitioners: 1.0 AANP contact hour Released: July 13, 2020 Expired: July 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue